APLT Stock Forecast 2025-2026
Distance to APLT Price Targets
APLT Price Momentum
10 Quality Stocks Worth Considering Now
Researching Applied Therapeutics (APLT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on APLT and similar high-potential opportunities.
Latest APLT Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, APLT has a neutral consensus with a median price target of $5.00 (ranging from $1.50 to $13.00). Currently trading at $0.55, the median forecast implies a 801.4% upside. This outlook is supported by 2 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yigal Nochomovitz at Citigroup, projecting a 2,243.6% upside. Conversely, the most conservative target is provided by Brian Abrahams at RBC Capital, suggesting a 170.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
APLT Analyst Ratings
APLT Price Target Range
Latest APLT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for APLT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 23, 2024 | William Blair | Sami Corwin | Market Perform | Downgrade | $0.00 |
| Dec 20, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $1.50 |
| Dec 2, 2024 | UBS | Esther Rajavelu | Neutral | Downgrade | $2.00 |
| Nov 29, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $8.00 |
| Nov 29, 2024 | Baird | Brian Skorney | Outperform | Maintains | $5.00 |
| Nov 29, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Downgrade | $4.00 |
| Nov 27, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $13.00 |
| Sep 19, 2024 | Leerink Partners | Joseph Schwartz | Outperform | Maintains | $14.00 |
| Sep 19, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $11.00 |
| Aug 27, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $8.00 |
| Jul 31, 2024 | William Blair | Tim Lugo | Outperform | Initiates | $0.00 |
| Jul 17, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $12.00 |
| Apr 11, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $12.00 |
| Mar 26, 2024 | RBC Capital | Brian Abrahams | Outperform | Initiates | $12.00 |
| Mar 15, 2024 | UBS | Esther Rajavelu | Buy | Maintains | $13.00 |
| Mar 6, 2024 | UBS | Esther Rajavelu | Buy | Maintains | $12.00 |
| Feb 22, 2024 | Leerink Partners | Joseph Schwartz | Outperform | Initiates | $12.00 |
| Feb 16, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $7.00 |
| Apr 25, 2023 | Baird | Brian Skorney | Outperform | Maintains | $14.00 |
| Apr 5, 2023 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $5.00 |
Applied Therapeutics Inc. (APLT) Competitors
The following stocks are similar to Applied Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Applied Therapeutics Inc. (APLT) Financial Data
Applied Therapeutics Inc. has a market capitalization of $65.12M with a P/E ratio of -0.4x. The company generates $-212,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -15.3% quarter-over-quarter, while maintaining an operating margin of -24,379.5% and return on equity of +698.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Applied Therapeutics Inc. (APLT) Business Model
About Applied Therapeutics Inc.
Develops innovative treatments for rare diseases.
Applied Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development of novel therapies for diseases with high unmet medical needs. The company generates value by advancing its product pipeline, which includes treatments for rare metabolic and inflammatory conditions, and potentially monetizing successful therapies through partnerships, sales, or licensing agreements.
Headquartered in New York City, the company emphasizes scientific innovation and aims to address significant therapeutic gaps, particularly in orphan diseases. Its commitment to research and development positions it as a key player in the biotechnology sector, potentially leading to improved health outcomes for patients.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
37
CEO
Mr. Les D. Funtleyder
Country
United States
IPO Year
2019
Website
www.appliedtherapeutics.comApplied Therapeutics Inc. (APLT) Latest News & Analysis
Dr. Baumgartner will lead Applied's efforts in preparing for upcoming regulatory interactions, potentially impacting the company's compliance and operational strategies.
Dr. Baumgartner's role in preparing for regulatory interactions suggests potential product advancements or approvals, impacting Applied's market position and future revenue.
Levi & Korsinsky, LLP has filed a class action lawsuit for investors in Applied Therapeutics (NASDAQ: APLT) over alleged securities fraud occurring from January 3 to December 2, 2024.
The class action lawsuit against Applied Therapeutics could lead to significant financial liabilities and impact stock value, signaling potential risks for current and prospective investors.
Investors in Applied Therapeutics, Inc. (NASDAQ:APLT) who experienced losses may explore recovery options under federal securities laws. More information is available through the provided link.
Lawsuits related to securities can impact stock prices and investor sentiment. News of potential recovery options may signal ongoing legal issues, affecting market perception of Applied Therapeutics.
A class action lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ:APLT) for alleged federal securities law violations, affecting investors who acquired shares between January 3 and December 2, 2024.
The class action lawsuit against Applied Therapeutics may lead to financial liability and reputational damage, potentially affecting stock performance and investor confidence in the company.
Rosen Law Firm alerts investors who bought Applied Therapeutics (NASDAQ:APLT) securities from Jan 3, 2024, to Dec 2, 2024, of a lead plaintiff deadline on Feb 18, 2025, for potential compensation.
The deadline for lead plaintiffs in a securities class action against Applied Therapeutics could affect stock prices and investor sentiment, potentially impacting future investments.
Investors in Applied Therapeutics, Inc. (NASDAQ: APLT) who incurred losses may explore potential recovery options under federal securities laws. Further details are available through a provided link.
The news indicates potential legal issues for Applied Therapeutics, which could lead to financial liabilities and impact stock performance, signaling risk for current and potential investors.
Frequently Asked Questions About APLT Stock
What is Applied Therapeutics Inc.'s (APLT) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Applied Therapeutics Inc. (APLT) has a median price target of $5.00. The highest price target is $13.00 and the lowest is $1.50.
Is APLT stock a good investment in 2025?
According to current analyst ratings, APLT has 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for APLT stock?
Wall Street analysts predict APLT stock could reach $5.00 in the next 12 months. This represents a 801.4% increase from the current price of $0.55. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Applied Therapeutics Inc.'s business model?
Applied Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development of novel therapies for diseases with high unmet medical needs. The company generates value by advancing its product pipeline, which includes treatments for rare metabolic and inflammatory conditions, and potentially monetizing successful therapies through partnerships, sales, or licensing agreements.
What is the highest forecasted price for APLT Applied Therapeutics Inc.?
The highest price target for APLT is $13.00 from Yigal Nochomovitz at Citigroup, which represents a 2,243.6% increase from the current price of $0.55.
What is the lowest forecasted price for APLT Applied Therapeutics Inc.?
The lowest price target for APLT is $1.50 from Brian Abrahams at RBC Capital, which represents a 170.4% increase from the current price of $0.55.
What is the overall APLT consensus from analysts for Applied Therapeutics Inc.?
The overall analyst consensus for APLT is neutral. Out of 9 Wall Street analysts, 2 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are APLT stock price projections?
Stock price projections, including those for Applied Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
